Skip to main content
Clinical Trials/IRCT2016041920441N4
IRCT2016041920441N4Completed未知

Omega-3 in the prevention of contrast-induced nephropathy after percutaneous coronary intervention

Shiraz University of Medical Sciences, international branch0 sites80 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 80 years (—)
Sex
All

Inclusion Criteria

  • Inclusion criteria included GFR more than 60 ml/min/1.73 m2; the ages of 18 to 80 years; patients undergoing elective PCI. Exclusion criteria: Pretreatment with N-acetyl cystein or intravenous vitamin C; sensitivity or tolerance to ASA or Clopidogrel or omega-3; sever adverse effects to drugs

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Shiraz University of Medical Sciences, international branch

Similar Trials